UNITED THERAPEUTICS Corp
For the period ended Sep 30, 2025. Filed Oct 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 29, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c)Trading Plans
On August 5, 2025, James Edgemond, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 129,517 stock options and sell the shares of our common stock received, subject to certain conditions.
On August 11, 2025, Paul Mahon, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 196,940 stock options and sell the shares of common stock received, subject to certain conditions.
On September 11, 2025, Jan Malcolm, amember of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 720 shares of our common stock, subject to certain conditions.
On September 30, 2025, Christopher Causey, amember of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 4,320 stock options and sell the shares of common stock received, subject to certain conditions.
During the three months ended September 30, 2025, no director or Section 16 officer terminated any Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).
| 56 | United Therapeutics, a public benefit corporation |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.